Scottish Medicines Consortium
SMC Evaluation Project
Laura McIver, Dr Paul Catchpole,
On behalf of SMC Evaluation Management Group
ABPI Conference, 17th November 2006
Scottish Medicines Consortium
Remit of Evaluation
• To assess the impact and effectiveness of SMC Advice in NHS Scotland
• To inform Scottish practice around managed introduction of new medicines
• To contribute to the wider understanding of organisations that assess new technologies
Scottish Medicines Consortium
Project team:Bill Ramsay
Marion BennieCorri Black
Vicky CairnsSharon HemsSamuel Oduro
NHS/IndustryGroups/Networks
Management group
SMC reference group
SMC
Project Team Links
Scottish Medicines Consortium
Industry and Organisations represented on the Reference Group
• Martin Coombes, AstraZeneca
• Andrew McGuigan, Janssen-Cilag
• Jim Swift, Takeda
• Patient and Public Representative
• Bipolar Fellowship Scotland
• HIV Scotland
• NHS ADTCs / Chief Executive / Director of Finance
• University Academics
• Scottish Executive Health Department
Scottish Medicines Consortium
Programme Elements
SMC Evaluation Programme
Impact of SMC decisions on medicines utilisation across the health care
system.
Evaluation of SMC budget
forecasts with resource
usage within NHS Scotland
over time
Evaluation of SMC’s
engagement with key
stakeholders
Supporting linkage of
clinical information
and medicines utilisation data
Scottish Medicines Consortium
Medicine Utilisation
Sample fromeach group selected. Reviewed and verified by
clinical networks and Reference Group
Classification of Medicines
Unique CancerAntimicrobials
Accepted Restricted
Not Recommended
Data (either per month or per quarter)
• volume/amount issued
• total cost/expenditure for the medicine
• no. of patients prescribed the medicine
Data Sources and CollectionPrimary care
- Information Services Division
Secondary Care- Pharmacy Systems and Clinicians
Pharmaceutical Industry
Scottish Medicines Consortium
Data Sources and Collection
Analysis of data and draft report
Validation and Interpretationvia
Clinical Networks, ADTC Networks,Reference Group and Industry
Issue report
Medicine Utilisation
Scottish Medicines Consortium
Classification of Data
Clinical Area
Recommendation type
Cancer Antimicrobials Unique / Innovative
Other Total
Accepted 10 4 1 53 68
Accepted for Restricted use
16 12 6 48 82
Not recommended
10 5 1 41 57
Total 36 21 8 142 207
Scottish Medicines Consortium
Not Recommended MedicinesNot Recommended Medicinesin Primary Carein Primary Care
£0
£5,000
£10,000
£15,000
£20,000
£25,000
£30,000
£35,000
£40,000
2002/0
3 Q
3
2002/0
3 Q
4
2003/0
4 Q
1
2003/0
4 Q
2
2003/0
4 Q
3
2003/0
4 Q
4
2004/0
5 Q
1
2004/0
5 Q
2
2004/0
5 Q
3
2004/0
5 Q
4
2005/0
6 Q
1
2005/0
6 Q
2
2005/0
6 Q
3
2005/0
6 Q
4
Financial Year Quarter
Gro
ss I
ng
red
ien
t C
ost
Note: GIC obtained from Prescribing Information System for Scotland (PRISMS)Note: GIC obtained from Prescribing Information System for Scotland (PRISMS)
Not Recommended by SMC Restricted approvalby NICE
Scottish Medicines Consortium
Outputs
• Scottish patients access to individual medicines reviewed by SMC
• Qualitative and quantitative data
• Generic key findings / learnings
• Recommendation next steps and actions
Scottish Medicines Consortium
SMC Evaluation Programme
Evaluation of SMC’s engagement
with key stakeholders.
Patient and Public Involvement Sub-Group (PAPIG)
Pharmaceutical Industry
NHS
Scottish Centre for SocialResearch
ADTC role and processes reviewed
Key themes identified
Opportunity exists to share experience and identify examples of good practice
Scottish Medicines Consortium
Engagement with Industry
• Industry can provide the project with important additional medicines uptake datasets:
• Secondary care
• Primary care
• To support both primary analysis (mainly secondary care) and to cross validate and supplement existing NHS datasets
• Evidence collection template (quantitative and qualitative data) presently being finalised for issue to companies
Scottish Medicines Consortium
Summary
• Work programme progressing well and to plan
• Challenges around data collection which can partially be addressed by engagement of industry
• Validation and interpretation needs to be robust
• Contextual qualitative evidence also required to support the quantitative information gathered
• ABPI and industry support crucial to the project
Top Related